Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery

The purpose of this study is to evaluate the safety and effectiveness of perioperative antiplatelet therapy in patients with drug-eluting stent undergoing non-cardiac surgery.

  • 2 views
  • 24 Jan, 2021
  • 5 locations
Clinical Study of Argatroban in the Treatment of Acute Progressive Ischemic Stroke

Acute ischemic stroke (AIS) has the characteristics of high morbidity, high mortality, high disability rate and high recurrence rate. Progressive cerebral infarction (PIS) is a subtype of AIS, accounting for 10% - 40%. Because of the gradual aggravation of neurological deficit symptoms, it has a higher rate of disability and …

  • 0 views
  • 24 Jan, 2021
  • 6 locations
Cardioprotective Properties of Natural Anti-Platelet Activating Factor Extract From Winery By-products in Healthy Women

The purpose of this study is to investigate the anti-platelet and anti-inflammatory properties of a winery by-products extract as well as to detect extract compounds and their metabolites in biological fluids. The study is a randomized, double-blind, crossover, placebo controlled postprandial study in healthy women.

  • 0 views
  • 24 Jan, 2021
  • 1 location
The Effect of Daily Mango Intake on Cardiovascular Health

hypothesize that the daily intake of 330 grams of mango (2 cups) will significantly increase PAT while reducing platelet aggregation after 2 hours and two weeks of daily intake.

  • 0 views
  • 24 Jan, 2021
  • 1 location
Ilomedin in Septic Shock With Persistent Microperfusion Defects (I-MICRO)

disorders. Ilomedin is a prostaglandin analog with a potent vasodilatory effect together with anti-thrombotic properties (inhibition of platelet aggregation) preferentially at the microcirculatory level. An

  • 0 views
  • 11 Nov, 2020
  • 1 location
Fostamatinib for Hospitalized Adults With COVID-19

Background COVID-19 is a new disease caused by SARS-CoV-2 that was identified in 2019. Some people who get sick with COVID-19 become ill requiring hospitalization. There are some medicines that may help with recovery. Researchers want to see if a drug called fostamatinib may help people who are hospitalized with …

  • 0 views
  • 09 Jan, 2021
  • 2 locations
Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer

The purpose of this study is to compare the gastric acid suppression profile among different regimen (Oral Vs Intravenous)of administration of proton pump inhibitor - Esomeprazole by 24hours intragastric pH monitoring.

proton pump inhibitors
peptic ulcer hemorrhage
  • 34 views
  • 07 Nov, 2020
  • 1 location
Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

This study represents the first trial to assess the efficacy of oral treprostinil therapy in patients with symptomatic primary or secondary Raynaud's Phenomenon (RP) resistant to vasodilatory therapy. The study will be randomized 1:1 UT-15C to placebo. The design is a crossover study and all subjects will be randomized to …

tadalafil
sildenafil
phosphodiesterase inhibitors
alpha adrenergic antagonists
scleroderma
  • 0 views
  • 24 Jan, 2021
  • 1 location
Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus

An AGE-rich diet can induce after 2-6 weeks persistent increases in mediators linked to vascular dysfunction (e.g. TNFα, VCAM-1) in people with type 2 diabetes mellitus (T2DM). Benfotiamine (BT), the liposoluble derivative of vitamin B1, blocks several pathways common to hyperglycaemia- and AGE-induced endothelial dysfunction. We have shown that advanced …

fasting
insulin resistance
insulin sensitivity
hyperglycemia
  • 1 views
  • 07 Nov, 2020
  • 1 location
Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment

The present study is designed for patients with mild COVID-19 phase, to demonstrate if there is a modification in the clinical evolution greater than or equal to 25% in their symptoms, implemented in two groups of patients under an early intervention treatment, a group ( A) will receive Azithromycin / …

  • 0 views
  • 28 Dec, 2020
  • 1 location